Current Report Filing (8-k)
June 10 2016 - 3:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d) of The
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported)
June
10, 2016
VACCINOGEN, INC.
(Exact Name of Registrant as Specified in
its Charter)
|
Maryland
|
000-54997
|
14-1997223
|
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
|
949 Fell Street, Baltimore, MD
|
21231
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(410)
387-4000
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2.below):
|
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 7 – Regulation FD
Item 7.01 Regulation FD Disclosure.
Vaccinogen has filed a new patent application related to methods
of characterizing antigenic determinants which broadly define adenocarcinomas with the guidance of human monoclonal antibodies
(HuMabs) reactive to such epitopes. One aspect involves characterization of the critical antigenic determinants (epitopes) with
a high degree of inter- and intra-tumoral incidence across a broad range of adenocarcinomas. The patent application also
relates to the physical recapitulation of the epitopes, generating a cohort of specific peptides, which may be useful for vaccinating
humans against a wide range of adenocarcinomas using a limited number of homogeneous tumor antigens.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VACCINOGEN, INC.
|
|
|
|
|
|
Date: June 10, 2016
|
By:
|
/s/ Andrew L. Tussing
|
|
|
|
Andrew L. Tussing
|
|
|
|
Chairman and Chief Executive Officer
|